A new study indicates that a portion of patients with major depressive disorder (MDD) exhibit immune system abnormalities that mirror those found in inflammatory skin diseases. This discovery raises the possibility that biologic drugs currently used in dermatology could be adapted to treat depression.
While MDD is a significant global health challenge, its precise biological causes remain unclear. Mounting evidence points to immune system dysregulation playing a role in some patients. Researchers compared blood proteomic profiles from individuals with MDD, atopic dermatitis, psoriasis, and healthy controls. They observed that MDD patients displayed an immune activation pattern akin to atopic dermatitis, specifically a leaning towards T helper 2 (Th2) immune responses.
The team's in-silico analysis identified dupilumab, a biologic drug that targets the interleukin-4 receptor alpha (IL-4Rα) subunit, as a promising candidate for repurposing. Computational modeling suggested dupilumab could reverse key inflammatory abnormalities seen in MDD patients.
Further experimental validation in a mouse model of chronic stress demonstrated that inhibiting IL-4Rα prevented the development of stress-induced social avoidance, a behavior relevant to depression.
These findings provide compelling molecular and preclinical data linking the Th2 immune axis to MDD and advocate for the investigation of targeted immunotherapies as potential disease-modifying treatments. The study also underscores the value of cross-disciplinary drug repurposing, suggesting dermatology advancements could inform future precision psychiatry.